The sales for antihypertensive medicine in Norway are projected to remain constant at 12.6 million USD from 2024 to 2028. Given the series is expressed in values (USD), it is important to note the sales value stood at 12.6 million USD in 2023 as well. This indicates no year-on-year variation in percentage, suggesting a flat trend over the last two years. The Compound Annual Growth Rate (CAGR) over the last 5 years also equates to 0%, reinforcing the consistency in sales value.
Future trends to watch for include potential influences from demographic changes such as aging population, changing healthcare policies, advances in hypertension treatment, and economic factors that could impact healthcare spending. Monitoring these factors may help identify shifts in this currently stable market.
